Sanjiv Patel - Jul 25, 2024 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President and CEO, Director
Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jul 25, 2024
Transactions value $
-$353,925
Form type
4
Date filed
7/29/2024, 06:37 PM
Previous filing
Jul 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $252K +50K +6.53% $5.04 816K Jul 25, 2024 Direct F1, F2
transaction RLAY Common Stock Sale -$458K -50K -6.13% $9.16 766K Jul 25, 2024 Direct F1, F2, F3
transaction RLAY Common Stock Options Exercise $185K +36.7K +4.79% $5.04 803K Jul 26, 2024 Direct F1, F2
transaction RLAY Common Stock Sale -$333K -36.7K -4.57% $9.07 766K Jul 26, 2024 Direct F1, F2, F4
holding RLAY Common Stock 675K Jul 25, 2024 By The Patel Family Irrevocable Trust of 2019 F5
holding RLAY Common Stock 687K Jul 25, 2024 By The SSP Irrevocable Trust of 2020 F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -50K -8.79% $0.00 519K Jul 25, 2024 Common Stock 50K $5.04 Direct F1, F6
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -36.7K -7.08% $0.00 482K Jul 26, 2024 Common Stock 36.7K $5.04 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024.
F2 Includes 762,360 shares underlying restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $9.00 to $9.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 This transaction was executed in multiple trades at prices ranging from $9.00 to $9.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F6 The shares underlying this option vested in sixteen (16) equal quarterly installments after April 23, 2019.